Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Net sales	$ 536,880	$ 572,619	$ 1,108,524	$ 1,126,598
Cost of goods sold	243,892	264,850	498,168	507,067
Gross profit	292,988	307,769	610,356	619,531
Selling, general and administrative expense	189,262	201,257	382,954	408,838
Research and Development Expense	51,984	50,122	101,287	97,697
Segment profit (loss)	51,742	56,390	126,115	112,996
Interest expense	5,740	5,841	11,430	11,827
Foreign exchange (gains) losses, net	774	1,233	1,702	2,513
Marketable Securities, Unrealized (Gain) Loss	(1,183,488)	(716,389)	(2,011,159)	(1,775,619)
Other Nonoperating Income (Expense)	17,229	3,896	20,502	22,592
Income before income taxes	1,245,945	769,601	2,144,644	1,896,867
(Provision) benefit for income taxes	(279,516)	(170,791)	(492,303)	(432,862)
Net income attributable to Bio-Rad	$ 966,429	$ 598,810	$ 1,652,341	$ 1,464,005
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 32.59	$ 20.08	$ 55.52	$ 49.12
Weighted average common shares - basic	29,652	29,814	29,759	29,807
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 32.15	$ 19.86	$ 54.84	$ 48.60
Weighted average common shares - diluted	30,058	30,154	30,131	30,125